Thomas J Hwang

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2015-2023
Publications (10 Years): 5

Top Topics

Drug Administration

Lymph Node Metastasis

Ejection Fraction

Top Venues

JCO oncology practice

JMIR public health and surveillance

BMJ (Clinical research ed.)

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas J Hwang
Reply to E. Noguchi et al. JCO oncology practice (2023)
Thomas J Hwang, Aaron S Kesselheim, Ariadna Tibau, ChangWon C Lee, Kerstin N Vokinger
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO oncology practice 18 (9) (2022)
Thomas J Hwang, Joseph S Ross, Kerstin N Vokinger, Aaron S Kesselheim
Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ (Clinical research ed.) 371 (2020)
Thomas J Hwang, Bishal Gyawali
Association between progression-free survival and patients' quality of life in cancer clinical trials. International journal of cancer 144 (7) (2018)
Michael S Sinha, Clark C Freifeld, John S Brownstein, Macarius M Donneyong, Paula Rausch, Brian M Lappin, Esther H Zhou, Gerald J Dal Pan, Ajinkya M Pawar, Thomas J Hwang, Jerry Avorn, Aaron S Kesselheim
Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. JMIR public health and surveillance 4 (1) (2018)
Jenny Hwang, Thomas J Hwang, Joseph B Ciolino
Pivotal clinical trials of novel ophthalmic drugs and medical devices: retrospective observational study, 2002-2012. BMJ open 5 (6) (2015)